Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on…
CYB004
Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Cybin demonstrated their proof of concept for…
Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin….
Cybin (CYBN.NE) announced its plans to advance the pre-clinical work for two of its molecules: its orally dissolving tablet (ODT) formulation CYB003 and its inhaled formulation CYB004. These…